Genmab — Juli 2015
-
Jeg kan godt acceptere 2000 nohope. ingen grund til at blive nærig
-
Lidt J&J Q2 forventninger .. http://www.marketwatch.com/story/what-to-expect-from-johnson-johnsons-earnings-2015-07-13
-
"Analyst Jayson Bedford at Raymond James said J&J has one of the strongest balance sheets among the larger medical technology sectors, but hasn’t been overly active on the mergers-and-acquisitions front over the last year despite growth in deal volume within the sector.
" -
"Bedford said he believes that to be the case because J&J has been more selective, and more focused on growth than on just making acquisitions to increase scale or near-term financial reasons, such as tax benefits.
Therefore, he expects “capital deployment to be a dominant topic” on J&J’s post-earnings conference call, as he anticipates more activity by year end.
" -
Forløbig en dag hvor der pustes lidt ud.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind